Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

Mark A Ainsworth; Klaus Bendtzen; Jørn Brynskov

doi:10.1111/j.1572-0241.2007.01638.x

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

Mark A Ainsworth, Klaus Bendtzen, Jørn Brynskov

158 Citationer (Scopus)

Abstract

To investigate if the combined assessment of anti-infliximab antibodies (Ab) and the degree of TNF-alpha binding capacity (TNF-alpha-BC) afforded by infliximab may predict the response to infliximab treatment in patients with Crohn's disease (CD).

Originalsprog	Engelsk
Tidsskrift	The American journal of gastroenterology
Vol/bind	103
Udgave nummer	4
Sider (fra-til)	944-8
Antal sider	5
DOI	https://doi.org/10.1111/j.1572-0241.2007.01638.x
Status	Udgivet - 1 apr. 2008
Udgivet eksternt	Ja

Adgang til dokumentet

10.1111/j.1572-0241.2007.01638.x

Andre filer og links

Link to publication in Scopus

Citationsformater

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. / Ainsworth, Mark A; Bendtzen, Klaus; Brynskov, Jørn.
I: The American journal of gastroenterology, Bind 103, Nr. 4, 01.04.2008, s. 944-8.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{044a91abb3a44af396648db73c4b77b8,

title = "Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease",

abstract = "To investigate if the combined assessment of anti-infliximab antibodies (Ab) and the degree of TNF-alpha binding capacity (TNF-alpha-BC) afforded by infliximab may predict the response to infliximab treatment in patients with Crohn's disease (CD).",

author = "Ainsworth, \{Mark A\} and Klaus Bendtzen and J{\o}rn Brynskov",

year = "2008",

month = apr,

day = "1",

doi = "10.1111/j.1572-0241.2007.01638.x",

language = "English",

volume = "103",

pages = "944--8",

journal = "The American journal of gastroenterology",

issn = "1572-0241",

publisher = "Wolters Kluwer Health",

number = "4",

}

TY - JOUR

T1 - Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

AU - Ainsworth, Mark A

AU - Bendtzen, Klaus

AU - Brynskov, Jørn

PY - 2008/4/1

Y1 - 2008/4/1

N2 - To investigate if the combined assessment of anti-infliximab antibodies (Ab) and the degree of TNF-alpha binding capacity (TNF-alpha-BC) afforded by infliximab may predict the response to infliximab treatment in patients with Crohn's disease (CD).

AB - To investigate if the combined assessment of anti-infliximab antibodies (Ab) and the degree of TNF-alpha binding capacity (TNF-alpha-BC) afforded by infliximab may predict the response to infliximab treatment in patients with Crohn's disease (CD).

UR - https://www.scopus.com/pages/publications/41849135759

U2 - 10.1111/j.1572-0241.2007.01638.x

DO - 10.1111/j.1572-0241.2007.01638.x

M3 - Journal article

C2 - 18028512

SN - 1572-0241

VL - 103

SP - 944

EP - 948

JO - The American journal of gastroenterology

JF - The American journal of gastroenterology

IS - 4

ER -

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater